Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992766050> ?p ?o ?g. }
- W1992766050 endingPage "248" @default.
- W1992766050 startingPage "242" @default.
- W1992766050 abstract "Background & AimsChronic hepatitis C increases mortality of patients with end-stage renal disease (ESRD). Ribavirin is not recommended for patients with renal dysfunction; peginterferon monotherapy is the most appropriate treatment for chronic hepatitis C in such patients. We evaluated the efficacy and safety of 2 dosages of peginterferon alfa-2a (40 kDa) in patients with chronic hepatitis C and ESRD on hemodialysis.MethodsWe performed a randomized, multicenter, open-label clinical study of 85 patients with chronic hepatitis C and ESRD who were receiving hemodialysis at specialist outpatient hepatology clinics. Patients were treated with subcutaneous peginterferon alfa-2a (40 kDa) at dosages of 135 or 90 μg/wk for 48 weeks.ResultsThe incidences of overall sustained virologic responses (SVRs) (undetectable hepatitis C virus [HCV] RNA [<50 IU/mL] after 24 weeks of untreated follow-up) were 39.5% (15/38) in the 135 μg/wk group and 34.9% (15/43) in the 90 μg/wk group (odds ratio, 1.22; 95% confidence interval, 0.49–3.06; P = .67). Among patients with undetectable HCV RNA at week 12, 60.9% (14/23) of those in the 135 μg/wk group and 87.5% (14/16) of those in the 90 μg/wk group achieved an SVR. Therapy was well-tolerated with no new safety concerns. The most common adverse events (>10% of patients in at least 1 treatment group) included conditions associated with ESRD (anemia and hypertension) and with interferon treatment.ConclusionsForty-eight weeks of treatment with low-dose peginterferon alfa-2a (40 kDa) is safe and produces an SVR in 35%–40% of patients with chronic hepatitis C and ESRD on hemodialysis. Chronic hepatitis C increases mortality of patients with end-stage renal disease (ESRD). Ribavirin is not recommended for patients with renal dysfunction; peginterferon monotherapy is the most appropriate treatment for chronic hepatitis C in such patients. We evaluated the efficacy and safety of 2 dosages of peginterferon alfa-2a (40 kDa) in patients with chronic hepatitis C and ESRD on hemodialysis. We performed a randomized, multicenter, open-label clinical study of 85 patients with chronic hepatitis C and ESRD who were receiving hemodialysis at specialist outpatient hepatology clinics. Patients were treated with subcutaneous peginterferon alfa-2a (40 kDa) at dosages of 135 or 90 μg/wk for 48 weeks. The incidences of overall sustained virologic responses (SVRs) (undetectable hepatitis C virus [HCV] RNA [<50 IU/mL] after 24 weeks of untreated follow-up) were 39.5% (15/38) in the 135 μg/wk group and 34.9% (15/43) in the 90 μg/wk group (odds ratio, 1.22; 95% confidence interval, 0.49–3.06; P = .67). Among patients with undetectable HCV RNA at week 12, 60.9% (14/23) of those in the 135 μg/wk group and 87.5% (14/16) of those in the 90 μg/wk group achieved an SVR. Therapy was well-tolerated with no new safety concerns. The most common adverse events (>10% of patients in at least 1 treatment group) included conditions associated with ESRD (anemia and hypertension) and with interferon treatment. Forty-eight weeks of treatment with low-dose peginterferon alfa-2a (40 kDa) is safe and produces an SVR in 35%–40% of patients with chronic hepatitis C and ESRD on hemodialysis." @default.
- W1992766050 created "2016-06-24" @default.
- W1992766050 creator A5011114835 @default.
- W1992766050 creator A5021496172 @default.
- W1992766050 creator A5029655580 @default.
- W1992766050 creator A5035004999 @default.
- W1992766050 creator A5036980554 @default.
- W1992766050 creator A5059508363 @default.
- W1992766050 creator A5061653039 @default.
- W1992766050 creator A5065383247 @default.
- W1992766050 creator A5073880705 @default.
- W1992766050 date "2011-03-01" @default.
- W1992766050 modified "2023-10-15" @default.
- W1992766050 title "Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease" @default.
- W1992766050 cites W1978231932 @default.
- W1992766050 cites W1991815197 @default.
- W1992766050 cites W1996434966 @default.
- W1992766050 cites W2009046415 @default.
- W1992766050 cites W2011707824 @default.
- W1992766050 cites W2018446644 @default.
- W1992766050 cites W2027545702 @default.
- W1992766050 cites W2028177473 @default.
- W1992766050 cites W2032911972 @default.
- W1992766050 cites W2046339229 @default.
- W1992766050 cites W2047208492 @default.
- W1992766050 cites W2058720438 @default.
- W1992766050 cites W2060574036 @default.
- W1992766050 cites W2076744707 @default.
- W1992766050 cites W2087073512 @default.
- W1992766050 cites W2112876622 @default.
- W1992766050 cites W2113864802 @default.
- W1992766050 cites W2119806249 @default.
- W1992766050 cites W2127685726 @default.
- W1992766050 cites W2128428904 @default.
- W1992766050 cites W2142578745 @default.
- W1992766050 cites W2151471855 @default.
- W1992766050 cites W2162456167 @default.
- W1992766050 cites W2164666960 @default.
- W1992766050 cites W2169430643 @default.
- W1992766050 cites W2314619766 @default.
- W1992766050 cites W2332630894 @default.
- W1992766050 cites W4232907328 @default.
- W1992766050 doi "https://doi.org/10.1016/j.cgh.2010.10.018" @default.
- W1992766050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21056689" @default.
- W1992766050 hasPublicationYear "2011" @default.
- W1992766050 type Work @default.
- W1992766050 sameAs 1992766050 @default.
- W1992766050 citedByCount "29" @default.
- W1992766050 countsByYear W19927660502012 @default.
- W1992766050 countsByYear W19927660502013 @default.
- W1992766050 countsByYear W19927660502014 @default.
- W1992766050 countsByYear W19927660502015 @default.
- W1992766050 countsByYear W19927660502016 @default.
- W1992766050 countsByYear W19927660502018 @default.
- W1992766050 countsByYear W19927660502023 @default.
- W1992766050 crossrefType "journal-article" @default.
- W1992766050 hasAuthorship W1992766050A5011114835 @default.
- W1992766050 hasAuthorship W1992766050A5021496172 @default.
- W1992766050 hasAuthorship W1992766050A5029655580 @default.
- W1992766050 hasAuthorship W1992766050A5035004999 @default.
- W1992766050 hasAuthorship W1992766050A5036980554 @default.
- W1992766050 hasAuthorship W1992766050A5059508363 @default.
- W1992766050 hasAuthorship W1992766050A5061653039 @default.
- W1992766050 hasAuthorship W1992766050A5065383247 @default.
- W1992766050 hasAuthorship W1992766050A5073880705 @default.
- W1992766050 hasConcept C126322002 @default.
- W1992766050 hasConcept C203014093 @default.
- W1992766050 hasConcept C2522874641 @default.
- W1992766050 hasConcept C2776235749 @default.
- W1992766050 hasConcept C2776408679 @default.
- W1992766050 hasConcept C2776455275 @default.
- W1992766050 hasConcept C2776461080 @default.
- W1992766050 hasConcept C2778063415 @default.
- W1992766050 hasConcept C2778248108 @default.
- W1992766050 hasConcept C2778653478 @default.
- W1992766050 hasConcept C2780040827 @default.
- W1992766050 hasConcept C3019040382 @default.
- W1992766050 hasConcept C41260117 @default.
- W1992766050 hasConcept C71924100 @default.
- W1992766050 hasConcept C90924648 @default.
- W1992766050 hasConceptScore W1992766050C126322002 @default.
- W1992766050 hasConceptScore W1992766050C203014093 @default.
- W1992766050 hasConceptScore W1992766050C2522874641 @default.
- W1992766050 hasConceptScore W1992766050C2776235749 @default.
- W1992766050 hasConceptScore W1992766050C2776408679 @default.
- W1992766050 hasConceptScore W1992766050C2776455275 @default.
- W1992766050 hasConceptScore W1992766050C2776461080 @default.
- W1992766050 hasConceptScore W1992766050C2778063415 @default.
- W1992766050 hasConceptScore W1992766050C2778248108 @default.
- W1992766050 hasConceptScore W1992766050C2778653478 @default.
- W1992766050 hasConceptScore W1992766050C2780040827 @default.
- W1992766050 hasConceptScore W1992766050C3019040382 @default.
- W1992766050 hasConceptScore W1992766050C41260117 @default.
- W1992766050 hasConceptScore W1992766050C71924100 @default.
- W1992766050 hasConceptScore W1992766050C90924648 @default.
- W1992766050 hasIssue "3" @default.
- W1992766050 hasLocation W19927660501 @default.
- W1992766050 hasLocation W19927660502 @default.